secwatch.observer — SEC 8-K summary
======================================

Issuer:     Enveric Biosciences, Inc. (ENVB)
CIK:        0000890821
Form:       8-K
Filed at:   2023-02-28T23:59:59+00:00
Accession:  0001493152-23-006267
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Enveric Biosciences appoints Kevin Coveney as CFO effective March 13, 2023; interim CFO Robert Dickey IV resigns
--------------------------------------------------------------------------------

- Kevin Coveney appointed CFO effective March 13, 2023, succeeding interim CFO Robert Dickey IV.
- Coveney receives $385,000 base salary, bonus up to 40% of base, and 26,500 RSUs vesting over 4 years.
- Coveney brings 30+ years biotech finance experience; previously CFO at Memgen and Q-State Biosciences.
- Interim CFO Robert Dickey IV resigns; resignation not due to any disagreement with company.
- Inducement RSU grant approved by board under NASDAQ Listing Rule 5635(c)(4).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/890821/000149315223006267/0001493152-23-006267-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/890821/000149315223006267/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-006267

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer